title: PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.
abstract: Diabetes is associated with a high risk for ischemic heart disease. We have previously shown that phosphodiesterase 5 inhibitor tadalafil (TAD) induces cardioprotection against ischemia/ reperfusion (I/R) injury in diabetic mice. Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug that has been reported to reduce hyperglycemia in diabetic patients. Therefore, we hypothesized that a combination of TAD and HCQ may induce synergistic cardioprotection in diabetes. We also investigated the role of insulin-Akt-mammalian target of rapamycin (mTOR) signaling, which regulates protein synthesis and cell survival. Adult male db/db mice were randomized to receive vehicle, TAD (6 mg/kg), HCQ (50 mg/kg), or TAD + HCQ daily by gastric gavage for 7 days. Hearts were isolated and subjected to 30-minute global ischemia, followed by 1-hour reperfusion in Langendorff mode. Cardiac function and myocardial infarct size were determined. Plasma glucose, insulin and lipid levels, and relevant pancreatic and cardiac protein markers were measured. Treatment with TAD + HCQ reduced myocardial infarct size (17.4% ± 4.3% vs. 37.8% ± 4.9% in control group,P< 0.05) and enhanced the production of ATP. The TAD + HCQ combination treatment also reduced fasting blood glucose, plasma free fatty acids, and triglyceride levels. Furthermore, TAD + HCQ increased plasma insulin levels (513 ± 73 vs. 232 ± 30 mU/liter,P< 0.05) with improved insulin sensitivity, larger pancreaticβ-cell area, and pancreas mass. Insulin-like growth factor-1 (IGF-1) levels were also elevated by TAD + HCQ (343 ± 14 vs. 262 ± 22 ng/ml,P< 0.05). The increased insulin/IGF-1 resulted in activation of downstream Akt/mTOR cellular survival pathway. These results suggest that combination treatment with TAD and HCQ could be a novel and readily translational pharmacotherapy for reducing cardiovascular risk factors and protecting against myocardial I/R injury in type 2 diabetes.
authors.affiliation: Pauley Heart Center, Division of Cardiology, Virginia Commonwealth University. Richmond, Virginia.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.affiliation: Pauley Heart Center, Division of Cardiology, Virginia Commonwealth University. Richmond, Virginia.
authors.forename: Lei
authors.initials: L
authors.lastname: Xi
authors.affiliation: Pauley Heart Center, Division of Cardiology, Virginia Commonwealth University. Richmond, Virginia rakesh.kukreja@vcuhealth.org.
authors.forename: Rakesh C
authors.initials: RC
authors.lastname: Kukreja
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000517:prevention & control*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006886:Hydroxychloroquine / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009203:Myocardial Infarction / Q000097:blood / Q000517:prevention & control*; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D000068581:Tadalafil / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007328:Insulin; D058986:Phosphodiesterase 5 Inhibitors; D006886:Hydroxychloroquine; D000068581:Tadalafil